Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Induction Therapy With Autologous Mesenchymal Stem Cells in Living-Related Kidney Transplants

Induction Therapy With Autologous Mesenchymal Stem Cells in Living-Related Kidney Transplants ORIGINAL CONTRIBUTION Induction Therapy With Autologous Mesenchymal Stem Cells in Living-Related Kidney Transplants A Randomized Controlled Trial Jianming Tan, MD, PhD Context Antibody-based induction therapy plus calcineurin inhibitors (CNIs) reduce acute rejection rates in kidney recipients; however, opportunistic infections and toxic Weizhen Wu, MD CNI effects remain challenging. Reportedly, mesenchymal stem cells (MSCs) have suc- Xiumin Xu, MS cessfully treated graft-vs-host disease. Lianming Liao, PhD Objective To assess autologous MSCs as replacement of antibody induction for pa- tients with end-stage renal disease who undergo ABO-compatible, cross-match– Feng Zheng, MD, PhD negative kidney transplants from a living-related donor. Shari Messinger, PhD Design, Setting, and Patients One hundred fifty-nine patients were enrolled in Xinhui Sun, MD this single-site, prospective, open-label, randomized study from February 2008-May Jin Chen, BS 2009, when recruitment was completed. Shunliang Yang, MD Intervention Patients were inoculated with marrow-derived autologous MSC (1−2 10 /kg) at kidney reperfusion and two weeks later. Fifty-three patients received Jinquan Cai, MD standard-dose and 52 patients received low-dose CNIs (80% of standard); 51 patients Xia Gao, MD in the control group received anti–IL-2 receptor antibody plus standard-dose CNIs. Antonello Pileggi, MD, PhD Main Outcome Measures The primary measure was 1-year incidence of acute http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Induction Therapy With Autologous Mesenchymal Stem Cells in Living-Related Kidney Transplants

Loading next page...
 
/lp/american-medical-association/induction-therapy-with-autologous-mesenchymal-stem-cells-in-living-DxrcI5Bflv
Publisher
American Medical Association
Copyright
Copyright 2012 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.2012.316
pmid
22436957
Publisher site
See Article on Publisher Site

Abstract

ORIGINAL CONTRIBUTION Induction Therapy With Autologous Mesenchymal Stem Cells in Living-Related Kidney Transplants A Randomized Controlled Trial Jianming Tan, MD, PhD Context Antibody-based induction therapy plus calcineurin inhibitors (CNIs) reduce acute rejection rates in kidney recipients; however, opportunistic infections and toxic Weizhen Wu, MD CNI effects remain challenging. Reportedly, mesenchymal stem cells (MSCs) have suc- Xiumin Xu, MS cessfully treated graft-vs-host disease. Lianming Liao, PhD Objective To assess autologous MSCs as replacement of antibody induction for pa- tients with end-stage renal disease who undergo ABO-compatible, cross-match– Feng Zheng, MD, PhD negative kidney transplants from a living-related donor. Shari Messinger, PhD Design, Setting, and Patients One hundred fifty-nine patients were enrolled in Xinhui Sun, MD this single-site, prospective, open-label, randomized study from February 2008-May Jin Chen, BS 2009, when recruitment was completed. Shunliang Yang, MD Intervention Patients were inoculated with marrow-derived autologous MSC (1−2 10 /kg) at kidney reperfusion and two weeks later. Fifty-three patients received Jinquan Cai, MD standard-dose and 52 patients received low-dose CNIs (80% of standard); 51 patients Xia Gao, MD in the control group received anti–IL-2 receptor antibody plus standard-dose CNIs. Antonello Pileggi, MD, PhD Main Outcome Measures The primary measure was 1-year incidence of acute

Journal

JAMAAmerican Medical Association

Published: Mar 21, 2012

References